Shattuck Labs is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of dual-function fusion proteins for oncology and autoimmune disease. The ARC platform consolidates checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics. Its lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals, and SL-172154 (SIRPα-Fc-CD40L) is planned to begin Phase I enrollment. The company anticipates adding another clinical program in 2021 and continuing to expand its pipeline. Shattuck has offices in Durham, North Carolina and Austin, Texas. It recently closed a $118 million Series B equity financing to accelerate clinical development of multiple programs.

Total raised

$118M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2020